Back
DRMA logo

Dermata Therapeutics Inc (DRMA)

Biotechnology
DRMA · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →
$1.72
+5.52%

Weekly undervalued picks

Price · 1 year
Loading live analysis…
Loading analysis…

Intrinsic Investor is for research and education only. Not financial advice.

Key metrics

EPS
$-8.16
ROE
-103.6%
Gross margin
0.0%
Debt/Equity
Revenue growth
P/B ratio
Beta
Forward P/E

Dermata Therapeutics Inc — company intelligence

Earnings surprises

Q2 2026$-0.74 vs $-0.56 est-31.9%
Q1 2026$-0.48 vs $-0.54 est+11.2%
Q4 2025$-1.52 vs $-1.57 est+3.2%
Q3 2025$-1.65 vs $-1.62 est-1.7%

Analyst consensus · 7 analysts

6 Buy1 Hold0 Sell
Updated Aug 25, 2026

Insider activity · 90 days

0 buys1 sellnet -11 shares
Scott Kathleen D.Sell 11 · Jun 16, 2026

AI Valuation Narrative

Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.

Weekly undervalued picks

Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.

Free. No spam. We only email once per week.

Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.